Prothena Corporation plc
25-28 North Wall Quay
Dublin
1
Tel: 353-1-902-3519
Fax: 353-1-902-3510
Website: http://www.prothena.com
Email: info@prothena.com
214 articles about Prothena Corporation plc
-
Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
4/18/2021
Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 points
-
Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021
4/15/2021
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that results from its Phase 1 study of PRX004 in ATTR amyloidosis have been selected for an oral presentation as part of the Emerging Science Session on Sunday, April 18th at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting
-
BioSpace Movers & Shakers, April 9
4/9/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 07, 2021
4/7/2021
Prothena Corporation plc, a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced that in connection with hiring Dr. Hideki Garren as Prothena’s Chief Medical Officer, the compensation committee of the Company’s board of directors granted Dr. Garren, an option to purchase 250,000 ordinary shares of the Company.
-
Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
4/5/2021
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer.
-
Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares
3/24/2021
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that it priced an underwritten public offering of 3,500,000 of its ordinary shares at a price to the public of $20.75 per ordinary share,
-
Prothena Announces Proposed Offering of Ordinary Shares - Mar 23, 2021
3/23/2021
Prothena Corporation plc, a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced that it has commenced an underwritten public offering of its ordinary shares.
-
Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021
3/8/2021
Prothena Corporation plc, a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, will hold an investor webcast Thursday, March 11, at 4:30 PM ET to review three oral presentations made at The 15th International Conference on Alzheimer’s and Parkinson’s Diseases.
-
Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
2/24/2021
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced three oral presentations and participation in a live forum at The 15th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2021
-
Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
2/11/2021
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today reported financial results for the fourth quarter and full year 2020.
-
It was a busy week for clinical trial updates. Here’s a look.
-
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 05, 2021
2/5/2021
Prothena Corporation plc, a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced that in connection with hiring three new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 75,000 ordinary shares of the Company.
-
Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th
2/4/2021
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced today that it will report its fourth quarter and full year 2020 financial results on Thursday, February 11, 2021
-
Prothena said it anticipates beginning the Phase III study of birtamimab, previously known as NEOD001, in mid-2021.
-
Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
2/1/2021
Prothena Corporation plc (NASDAQ:PRTA) today announced that following further analyses by the Company and multiple in-depth discussions with the U.S. Food and Drug Administration (FDA) regarding the previous analysis of patients categorized as Mayo Stage IV at baseline in the VITAL study, Prothena is advancing birtamimab into the confirmatory Phase 3 AFFIRM-AL study in this category of patients with AL amyloidosis
-
Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies
12/10/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
12/9/2020
Slowing of neuropathy progression for all 7 evaluable patients , evidenced by a +1.29 point mean change in NIS , was more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of – 3.33 points I mprovement in cardiac function for all 7 evaluable patients demonstrated by a decrease in global longitudinal strain (GLS) Investor conference call and webcast
-
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 04, 2020
12/4/2020
Prothena Corporation plc announced that in connection with hiring two new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 90,000 ordinary shares of the Company.
-
Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
11/4/2020
Prothena Corporation plc, a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, reported financial results for the third quarter and first nine months of 2020.
-
Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
11/4/2020
Next generation anti- Aβ antibod ies being developed for subcutaneous administration to improve access for patient s with Alzheimer’s disease Multi- i mmunogen Aβ- t au va ccine being developed for the prevention and treatment of Alzheimer’s disease